Related Experiment Video

Updated: Jun 23, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

[Advance of research on relationship between ABCG2 and drug resistance in hematologic malignancies - review]

Shi-Qiang Qu1, Zheng-Zheng Fu, De-Pei Wu

  • 1Jiangsu Institute of Hematology, The First Affiliated Hospital, Suzhou University, Suzhou 215006, Jiangsu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|April 22, 2009
PubMed

Insights

This study reviews ATP-binding cassette sub-family G member 2 (ABCG2) gene polymorphisms, their link to stem cells and tyrosine kinase inhibitors, and drug resistance in blood cancers.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Oncology

Background:

  • ATP-binding cassette sub-family G member 2 (ABCG2) is a transporter protein crucial for effluxing toxins and drugs.
  • ABCG2 mediates multidrug resistance, impacting chemotherapy efficacy.
  • ABCG2 plays a role in stem cell biology and tissue protection.

Purpose of the Study:

  • To review advances in research on ABCG2 single nucleotide polymorphisms (SNPs).
  • To explore the relationship between ABCG2, stem cells, and tyrosine kinase inhibitors (TKIs).
  • To analyze drug resistance in hematologic malignancies concerning ABCG2.

Main Methods:

  • Literature review and retrospective analysis of research on ABCG2.
  • Examination of studies on ABCG2 SNPs and their clinical relevance.
  • Analysis of drug resistance mechanisms in hematologic malignancies involving ABCG2.

Main Results:

  • ABCG2 SNPs are associated with variations in drug response and TKI efficacy.
  • The role of ABCG2 in stem cell populations influences treatment outcomes.
  • Understanding ABCG2 is key to overcoming multidrug resistance in blood cancers.

Conclusions:

  • ABCG2 polymorphisms significantly impact chemotherapy and TKI effectiveness.
  • Targeting ABCG2 presents a potential strategy to overcome drug resistance in hematologic malignancies.
  • Future research should focus on personalized medicine approaches based on ABCG2 status.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...